Objective: Our goal is to investigate the distribution of MEFV mutations in patients with renal amyloidosis who are in renal transplant waiting list which is prepared for transplantation.
Introduction
Familial Mediterranean fever (FMF) is an inherited disorder of an autosomal recessive trait. The major clinical finding of FMF is recurrent and self-limited attacks of fever. Severe abdominal, articular and/or chest pain due to inflammation of the peritoneum, synovia or pleura usually accompany these episodes. Between attacks, FMF patients are usually free of symptoms. The most important complication of FMF is progressive systemic amyloidosis, a situation leading to renal failure, which can be fatal [1] [2] [3] .
The discovery in 1997 of the gene responsible for FMF (MFEV) has gone a long way towards understanding its molecular basis. FMF gene encodes a protein known as pyrin that is thought to modulate apopitosis and NF-KB activation. Now almost 70 mutations have been detected, most of them on exon 10. Six mutations were discovered on exon 2 and one or two mutations on each of exons 1, 3, 5, and 9. Colchicine treatment is effective in treating or aborting the acute recurrent exacerbations of the disease and in preventing the development of amyloidosis [4] [5] [6] [7] . The aim of this study was to explore the magnitude of the FMF problem and to describe clinical phenotypic and genotypic profile in dialysis patients. It is also imperative to diagnose amyloidosis early enough to start the appropriate treatment and care. of painful and febrile attacks. The attacks were severe occurring in the abdomen, chest and joints, lasting from 24-72 hours. The history of attacks were mainly starting during childhood or adolescence. The laboratory findings of patients were elevated sedimentation rate, high acute phase reactant titres (CRP), increased serum amyloid A (SAA) and fibrinogen. These subjects were undergone biopsy for examining 25 amyloidosis taken from renal, rectal or duodenal. Amyloid deposition was obtained in 25 biopsies. Biopsy amyloidosis proven cases were analyzed for MEFV mutations. Human genomic DNA was obtained by extraction in the MagNa Pure LC System (Roch Applied Science) from 25 whole blood samples.
Materials and Methods

Patient
NanoChip Assay:
Oligonucleotids, primers, and probes used in the NanoChip assay were provided by Nanogen (San Diego, CA). The PCR for exon 2, 3, 5 and 10 of MEFV mutations were performed according to instructions in the Nanogen FMF Application note.
Main goal of the study is to assess phenotype-genotype correlations in FMF, specifically, the role of MEFV mutations for amyloidosis occurrence.
Results
The clinic feature of patients with amyloidosis has been presented in Table 1 .
The ratio of females to males is 0.6 (6:10) in patients with renal amyloidosis and is 0.8 (4:5) in patients with non renal amyloidosis. Consanguinity was documented in 4 of 25 (16%) of the patients. In our study population, most of the biopsies were taken from kidney. The remaining biopsies were not taken from the renal, so we do not know if the kidney has amyloidosis or not. Non renal amyloid deposition (rectum, duodenal) was present in renal chronic kidney disease patients. Here the question is if the primer of the disease is the different in non renal amyloidosis.
Discussion
In this study, we evaluated amyloidosis related renal failure patients rate within the renal transplantation waiting list and genotypes of patients. There are reports that FMF incidence is high in Turkey [8, 9] . In the study, 8.41% of waiting list appeared to be FMF patients. Abdominal pain attacks are the most common symptom and we believe that if the attacks are frequent, there is most probable amyloidosis leading to renal failure. It is, therefore, important to diagnosis of the disease as early as possible before amyloidosis initiating. Our series (FMF cases in renal waiting list) at this moment is not large, so it is difficult to make evaluation between genotype of patients and amyloidosis. There is regional study performed on pediatric group reported that M694V mutation is the most common one [10] .
It has been known that the onset of the FMF occurs before age of 30. The relation between renal failure and FMF is the occurrence of amyloidosis. Kidneys are seriously affected by amyloidosis causing proteinuria and resulting in renal failure. Dialysis and transplantation are choice of the treatments. Colchicine can prevent amyloidosis, it is, therefore imperative in the care of FMF patients to diagnose amyloid deposition early enough to begin treatment.
Many studies have investigated various parameters for the risk of amyloidosis. Although there is no consensual conclusion, the chief risk factor for renal amyloidosis in FMF is the pyrine gene mutations. In our study all cases caries either homozygote or compound heterozygote mutations of the gene. It appears indisputable that a given allele combinations at the gene locus contribute to manifestations of the disease, notably, amyloidosis. Our results have quite important ramifications from a practical point of view. The importance of the diagnosis and treatment of FMF in patients with overt disease living in region where the disease is identified as high risk brings serious responsibilities such as initiating prophylactic treatment with colchicine to asymptomatic individuals who are incidentally discovered to be pyrine gene mutations.
It should be considered that the FMF Patients in this study had a different mutation combination, which could display intercultural interactions and these mutations seem to be not different in respect to clinical presentation. 
